TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated


Options:
A: Arm Label: Internet-based stepped care; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based stepped care | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based stepped care; Assigned to Arm(s): Internet-based stepped care
B: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm
C: Arm Label: FitNet treatment; Type: EXPERIMENTAL; Interventions: Behavioral: FitNet treatment | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: FitNet treatment; Assigned to Arm(s): FitNet treatment | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated


Options:
A: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
B: Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram
C: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequenced Treatment Alternatives to Relieve Depression
Brief Summary: STAR\*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: Citalopram + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pindolol | Arm Label: Citalopram + pindolol; Type: EXPERIMENTAL; Interventions: Drug: Pindolol | Intervention Type: DRUG; Name: Pindolol; Assigned to Arm(s): Citalopram + pindolol, Citalopram + placebo
C: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo
D: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project Sugar 2: Health Events Costs in Diabetic Blacks
Brief Summary: Diabetes mellitus imposes a major burden on the public health of the United States, leading annually to over 300,000 deaths and over $130 billion in costs. This burden falls disproportionately upon ethnic minority groups, particularly African Americans, who are at excess risk for the development of type 2 diabetes and for a variety of its most serious complications. Suboptimal health care - in terms of access, quality, and adherence -appears to be an important contributing factor. Prior work suggests two possible approaches aimed at prevention to enhance risk factor control in outpatients with type 2 diabetes. One approach uses Nurse Case Managers (NCMs) to coordinate care plans with the provider team following protocols/clinical guidelines and algorithms designed to guide treatment including initiating and adjusting drug therapy, enhancing continuity of care, promoting interventions and self-management which include educational and behavioral strategies incorporating feedback and self-regulation. Another approach uses Community Health Workers (CHWs) to enhance culturally sensitive outreach, linkage, and monitoring service; to provide important patient and family education; and to improve access to and continuity of care. Results indicate that this intensive team approach, compared to usual care alone, produces substantial improvements in metabolic control. However, the cost-effectiveness of such interventions is unknown in the ''real-world''.

This has led to our current study, a randomized controlled trial within a managed care organization to determine the effects of a NCM/CHW team on metabolic control, on the occurrence of diabetes-related health events, health care utilization, and on direct health care costs. The participants will be African American adults with type 2 diabetes who receive primary care within a managed care organization in inner-city Baltimore.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nurse Case Manager and Community Health Worker Team; Assigned to Arm(s): N/A
B: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
C: Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention
D: Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Arm Label: Late implementation; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Early Intervention | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Late implementation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Treatment for Spinal Stenosis
Brief Summary: Lumbar spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) is a condition that occurs frequently, particularly in the elderly. This condition can lead to significant pain and limit a person's ability to function. Moreover, doctors disagree about the best way to treat people with lumbar spinal stenosis.

In this study we will compare surgical treatment of lumbar spinal stenosis with nonsurgical treatment using physical therapy. The results of this study should help clarify which treatment strategies are the most effective for patients with lumbar spinal stenosis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2
C: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery
D: Arm Label: Decompression without fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression without fusion | Arm Label: Decompression with fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression with fusion | Intervention Type: PROCEDURE; Name: Decompression without fusion; Assigned to Arm(s): Decompression without fusion | Intervention Type: PROCEDURE; Name: Decompression with fusion; Assigned to Arm(s): Decompression with fusion

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial of Treatment for Spinal Stenosis
Brief Summary: Lumbar spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) is a condition that occurs frequently, particularly in the elderly. This condition can lead to significant pain and limit a person's ability to function. Moreover, doctors disagree about the best way to treat people with lumbar spinal stenosis.

In this study we will compare surgical treatment of lumbar spinal stenosis with nonsurgical treatment using physical therapy. The results of this study should help clarify which treatment strategies are the most effective for patients with lumbar spinal stenosis.


Options:
A: Arm Label: Vertos mild® Minimally-Invasive Lumbar Decompression; Type: ACTIVE_COMPARATOR; Interventions: Device: MILD® (Minimally Invasive Lumbar Decompression) | Arm Label: Epidural Steroid Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epidural Steroid Injection | Intervention Type: DEVICE; Name: MILD® (Minimally Invasive Lumbar Decompression); Assigned to Arm(s): Vertos mild® Minimally-Invasive Lumbar Decompression | Intervention Type: DRUG; Name: Epidural Steroid Injection; Assigned to Arm(s): Epidural Steroid Injection
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2
C: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery
D: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic
Brief Summary: The purpose of this study is to compare the Standard Medical Management (SMM) vs. SMM enhanced with additional education about addiction and recovery (Enhanced Medical Management, EMM)


Options:
A: Arm Label: Methadone; Type: OTHER; Interventions: Drug: Methadone | Arm Label: Buprenorphine/Naloxone; Type: OTHER; Interventions: Drug: Buprenorphine-Naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine-Naloxone; Assigned to Arm(s): Buprenorphine/Naloxone
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): 1, 2, 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
D: Arm Label: RBP-6000 300mg/100mg; Type: EXPERIMENTAL; Interventions: Drug: SUBOXONE, Drug: RBP-6000 | Arm Label: RBP-6000 300mg/300mg; Type: EXPERIMENTAL; Interventions: Drug: SUBOXONE, Drug: RBP-6000 | Arm Label: Placebo Matching 300 mg/100 mg RBP-6000; Type: PLACEBO_COMPARATOR; Interventions: Drug: SUBOXONE, Drug: Placebo | Arm Label: Placebo Matching 300 mg RBP-6000; Type: PLACEBO_COMPARATOR; Interventions: Drug: SUBOXONE, Drug: Placebo | Intervention Type: DRUG; Name: SUBOXONE; Assigned to Arm(s): Placebo Matching 300 mg RBP-6000, Placebo Matching 300 mg/100 mg RBP-6000, RBP-6000 300mg/100mg, RBP-6000 300mg/300mg | Intervention Type: DRUG; Name: RBP-6000; Assigned to Arm(s): RBP-6000 300mg/100mg, RBP-6000 300mg/300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Matching 300 mg RBP-6000, Placebo Matching 300 mg/100 mg RBP-6000

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection
Brief Summary: Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).


Options:
A: Arm Label: Daily Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid (INH) daily for 9 months | Arm Label: Weekly Isoniazid / Rifapentine; Type: EXPERIMENTAL; Interventions: Drug: RPT + INH once weekly for 3 months given by DOT | Intervention Type: DRUG; Name: RPT + INH once weekly for 3 months given by DOT; Assigned to Arm(s): Weekly Isoniazid / Rifapentine | Intervention Type: DRUG; Name: Isoniazid (INH) daily for 9 months; Assigned to Arm(s): Daily Isoniazid
B: Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: Rifampin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampin | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): Rifampin
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifapentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rifapentine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders
Brief Summary: This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).


Options:
A: Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: guanfacine; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
C: Arm Label: Arbaclofen; Type: EXPERIMENTAL; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A

Answer: A